Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,628 matching trials from the live ClinicalTrials.gov search.
Conditions
Surgical Site Infections, Surgical Wound Infection, Infections, Anti-Infective Agents
Interventions
nasal antimicrobial photodisinfection therapy
Combination Product
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Englewood, Colorado • Brandon, Florida • Largo, Florida + 9 more
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
Fisons
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Conditions
Cutaneous T Cell Lymphomas (CTCL), Mycosis Fungoides (MF)
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Clostridium Difficile
Interventions
Stool specimen
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Stromal Tumor, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Meningeal Chronic Myelogenous Leukemia, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
Interventions
imatinib mesylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
Interventions
Retapamulin (Altabax)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Months to 98 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

The Ohio State University Dermatology Biorepository

NCT03146676
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Pneumococcal Disease
Interventions
Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more
Conditions
Otomycosis
Interventions
miconazole 2% oil, vehicle oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
7 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Chula Vista, California • La Jolla, California • Roseville, California + 9 more
Conditions
Pneumococcal Disease
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
2,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
30
States / cities
Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Conditions
Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Drug
Lead sponsor
Douglas Pharmaceuticals America Ltd
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Brandon, Florida • Tampa, Florida
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
MicroPhage, Inc.
Industry
Eligibility
18 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Tuscon, Arizona • Los Angeles, California • Charleston, South Carolina
Conditions
Pneumonia, Bacterial, Community-acquired
Interventions
Ceftaroline, Levofloxacin
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Conditions
Bacteremia, Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
7 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Conditions
Bacterial Conjunctivitis
Interventions
Vigamox Ophthalmic Solution, BSS placebo
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin

NCT03211156
Conditions
Vaginitis Gardnerella
Interventions
Amoxicillin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Winston-Salem, North Carolina
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Months to 15 Months
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
35
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more
Conditions
Gram-Positive Bacterial Infections
Interventions
Synercid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
27 Weeks to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
6
States / cities
Oakland, California • Orange, California • Durham, North Carolina + 3 more
Conditions
Pulmonary Sarcoidosis, Lung Function
Interventions
levaquin; ethambutol; rifampin and azithromycin.
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more